Replies to post #120681 on Amarin Corp Plc (AMRN)

[Whalatane]

Ralphey. Re "but still remaining is the major issue which AMRN has not yet detected "

Which issue is this ?? New drugs in development ...they are at least 6-8 yrs behind if you include an Outcome study .
Re the DS issue ...the closest IMHO is Omega Via EPA that cost about $66 a month for 85% EPA ...you need to spend about $75 a month to get the equal amount of EPA found in 4 gms of Vascepa .( monthly basis )

So how much more then $75 a month will CAD patients pay / or insurers cover ...to have access to FDA approved EPA with an Outcome trial demonstrating benefit .
Currently Vascepa retails for around $300 a month ....If R-IT succeeds AMRN can dramatically increase its sales volume ...and also lower its price .
Patients prefer Rx vs DS given a choice , and IMHO will pay up for it if necessary even if the co pay is $100 a month

Do agree tho that if R-IT fails and no subgroup shows more then 20% RRR ...stock will be crushed

Kiwi

[jessellivermore]

Ralphey:

Why the persistent interest in Amarin? I heard some company has come with a new antisense drug which either cut trigs or is a PCSK9 inhibitor. Since I know (or at least I think I know) ...these drugs a too expensive, too complicated they are not "practical" and represent more a feat of science rather than a realistic cure...So do I immediately head over their board and start trashing their stock...no...

What's your deal...The future of Amarin or V is not going to revolve around the trig issue..R-I is not a trig trial, not dependent on trig lowering..Lowering Trig levels, particularly fasting levels, may or may not be effective in lowering CVD event risk..What R-I needs to do is lower CVD event risk using Vascepa in patients on statins...to a meaning extent. Trigs are simply a side issue..

":>) JL